Page last updated: 2024-12-05
mechlorethamine hydrochloride
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
mechlorethamine hydrochloride : The hydrochloride salt of mechlorethamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5935 |
| CHEMBL ID | 1201001 |
| CHEBI ID | 55368 |
| SCHEMBL ID | 3855 |
| MeSH ID | M0013174 |
Synonyms (156)
| Synonym |
|---|
| c5h12cl3n |
| erasol hydrochloride |
| bis(2-chloroethyl)methylamine hydrochloride |
| dichloromethyldiethylamine hydrochloride |
| mustine hydrochlor |
| methyl bis(.beta.-chloroethyl)amine, hydrochloride |
| di(2-chloroethyl)methylamine hydrochloride |
| mitoxine |
| .beta.,.beta.'-dichlorodiethyl-n-methylamine hydrochloride |
| nitrogranulogen hydrochloride |
| nitol 'takeda' |
| chloramin hydrochloride |
| 2-chloro-n-(2-chloroethyl)-n-methylethanamine hydrochlroide |
| 1,5-dichloro-3-methyl-3-azapentane hydrochloride |
| stickstofflost |
| methyldi(.beta.-chloroethyl)amine hydrochloride |
| embichin hydrochloride |
| hn2 hydrochloride |
| mustargen hydrochloride |
| n-methylbis(.beta.-chlorethyl)amine hydrochloride |
| mechlorethamine hydrochloride |
| diethylamine,2'-dichloro-n-methyl-, hydrochloride |
| methyldi(2-chloroethyl)amine hydrochloride |
| nsc-762 |
| diethylamine,2'-dichloro-n-methyl, hydrochloride |
| mustine hydrochloride |
| c 6866 |
| methylbis(.beta.-chloroethyl)amine hydrochloride |
| 2,2'-dichloro-n-methyldiethylamine hydrochloride |
| methylbis(2-chloroethyl)amine hydrochloride |
| n-methylbis(2-chloroethyl)amine hydrochloride |
| n-methyl-2,2'-dichlorodiethylamine hydrochloride |
| nsc-762 hydrochloride |
| mba hydrochloride |
| caryolysine hydrochloride |
| nitrogen mustard hydrochloride |
| nitol |
| chlormethine hydrochloride |
| dichloren hydrochloride |
| wln: g2n1&2g &gh |
| mechorethamine hydrochloride |
| 2,2'-dichloro-n-methyldiethylamino hydrochloride |
| PRESTWICK_37 |
| 55-86-7 |
| nci-c56382 |
| erasol-ido |
| chlorethamine |
| embikhine |
| chlormethinum |
| erasol |
| azotoyperite |
| nsc762 |
| nitol takeda |
| dema |
| dimitan |
| chloramin |
| sk 101 |
| dichloren |
| mustargen (tn) |
| valchlor (tn) |
| mechlorethamine hydrochloride (usp) |
| D04872 |
| NCGC00091835-01 |
| n,n-bis(2-chloraethyl)methylamin-hydrochlorid [german] |
| embiquine |
| einecs 200-246-0 |
| methyldi(beta-chloroethyl)amine hydrochloride |
| kloramin (van) |
| ethanamine, 2-chloro-n-(2-chloroethyl)-n-methyl-, hydrochloride |
| n,n-bis(2-chloroethyl)methylamine hydrochloride |
| zagreb |
| hsdb 7176 |
| ccris 448 |
| stickstofflost-ebewe |
| n-methyl-bis-beta-chlorethylamine hydrochloride |
| ai3-16195 |
| beta,beta'-dichlorodiethyl-n-methylamine hydrochloride |
| methyl-bis(beta-chloroethyl)amine hydrochloride |
| n-mustard [german] |
| diethylamine, 2,2'-dichloro-n-methyl, hydrochloride |
| mechlorethamine chloridrate |
| mustin hydrochloride |
| n-methyl-di-2-chloroethylamine hydrochloride |
| pliva |
| mechlorethamine hydrochloride, 98% |
| 2-chloro-n-(2-chloroethyl)-n-methylethanamine hydrochloride |
| nitrogen mustard hcl |
| n,n-bis(2-chloraethyl)methylamin-hydrochlorid |
| CHEBI:55368 , |
| n-mustard |
| mechlorethamine hcl |
| chlormethini hydrochloridum |
| CHEMBL1201001 |
| chlormethine hcl |
| l0mr697hhi , |
| mechlorethamine hydrochloride [usp] |
| nitrogen mustard (hn-2), hydrochloride |
| unii-l0mr697hhi |
| NCGC00258192-01 |
| tox21_200638 |
| cas-55-86-7 |
| dtxcid205757 |
| dtxsid8025757 , |
| tox21_111170 |
| S4252 |
| smr000059226 |
| MLS003899210 |
| BP-20221 |
| mechlorethamine hydrochloride [usp-rs] |
| mechlorethamine hydrochloride [mi] |
| mechlorethamine hydrochloride [hsdb] |
| chlormethini hydrochloridum [who-ip latin] |
| chlormethine hydrochloride [who-ip] |
| mechlorethamine hydrochloride [orange book] |
| chlormethine hydrochloride [who-dd] |
| mechlorethamine hydrochloride [vandf] |
| mechlorethamine hydrochloride [usp monograph] |
| chlormethine hydrochloride [mart.] |
| AKOS015915356 |
| SCHEMBL3855 |
| tox21_111170_1 |
| NCGC00091835-10 |
| CS-5080 |
| QZIQJVCYUQZDIR-UHFFFAOYSA-N |
| n,n-bis(chloroethyl)methylamine hydrochloride |
| 2-chloro-n-(2-chloroethyl) -n-methylethanamine hydrochloride |
| bis(2-chloroethyl)methylammonium chloride |
| bis-(2-chloroethyl)methylamine hydrochloride |
| 2-chloro-n-(chloroethyl)-n-methylethanamine hydrochloride |
| bis-(2-chloro-ethyl)-methyl-amine hydrochloride |
| bis-(2-chloroethyl)-methylamine hydrochloride |
| 1,5-dichloro-3-methyl-3-azapentane, hydrochloride |
| n-methylbis(2-chloroethyl)-amine hydrochloride |
| bis (2-chloroethyl)methyl amine hydrochloride |
| bis(2-chloroethyl)-methylamine hydrochloride |
| n,n-bis(2-chloroethyl)-n-methylamine hydrochloride |
| n-methylbis (2-chloroethyl)amine hydrochloride |
| bis (2-chloroethyl)-methylamine hydrochloride |
| n-methyl-bis-(2-chloroethyl)amine hydrochloride |
| bis(2-chloroethyl)methyl amine hydrochloride |
| 2-chloro-n-(2 -chloroethyl)-n-methylethanamine hydrochloride |
| bis-(2-chloroethyl)-methyl-amine hydrochloride |
| W-105542 |
| chloromethine hydrochloride |
| 2-chloro-n-(2-chloroethyl)-n-methylethanamine hydrochloride (1:1) |
| HY-B1253 |
| chlormethine (hydrochloride) |
| mfcd00012517 |
| bis(2-chloroethyl)-n-methylamine hydrochloride |
| SW220100-1 |
| 2-chloro-n-(2-chloroethyl)-n-methylethanamine;hydrochloride |
| Q27124263 |
| CCG-264667 |
| F11444 |
| bis(2-chloroethyl)methylamine-d4hydrochloride |
| SY003678 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (54)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 79.5108 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 50.1187 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 61.5166 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 22.4597 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 54.8267 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 22.3872 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 54.8267 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.8554 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 16.1248 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 29.7303 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 23.5746 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 15.8489 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 68.4501 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 45.4873 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 40.5828 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 37.6126 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533; AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 36.7154 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 31.4214 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 37.0629 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 56.9946 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220; AID743239 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 8.6174 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 45.1054 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| polyprotein | Zika virus | Potency | 22.3872 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 44.3155 | 0.0010 | 24.5048 | 61.6448 | AID588535; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 33.9195 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 61.5166 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| caspase-3 | Homo sapiens (human) | Potency | 23.5746 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 22.8319 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 18.9061 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 21.0995 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 29.0486 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 68.4501 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| hemoglobin subunit beta | Homo sapiens (human) | Potency | 19.9526 | 0.3162 | 9.0861 | 31.6228 | AID910 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 22.1061 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 10.0000 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 68.4501 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 9.0633 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 38.8144 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 20.1239 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 21.4215 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 26.6086 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 7.5686 | 0.0056 | 12.3677 | 36.1254 | AID624032; AID624044 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 3.1623 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 30.5756 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 12.7264 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743; AID720552 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 30.5756 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 26.6032 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 22.5581 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 21.0108 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (218)
Molecular Functions (61)
Ceullar Components (54)
Bioassays (34)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 32.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.99) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||